The federal settlement resolves allegations of unlawful controlled substance prescribing and absent patient records and restricts future DEA registration for certain controlled substances.
Dr. Twan Phanijphand, a Florida gastroenterologist, settled for $300,000 over allegations of unlawful prescribing of controlled substances. The settlement includes provisions for continued education and monitoring.
Background
The unlawful prescribing of controlled substances poses risks to patient safety and public health. Federal regulations, such as the Controlled Substances Act, mandate strict recordkeeping and responsible prescribing practices to prevent substance misuse and diversion.
Data Highlights
No numerical data or trial data available in the source material.
Key Findings
Dr. Phanijphand unlawfully prescribed at least 127 controlled substance prescriptions from June 15, 2023, through March 7, 2025.
Prescriptions included opioids and benzodiazepines without maintaining required patient records.
He voluntarily surrendered his DEA registration on April 22, 2026.
The settlement prohibits him from reapplying for DEA registration for Schedule II or IIN controlled substances.
The DEA emphasizes the importance of accurate recordkeeping to prevent substance diversion.
Clinical Implications
Healthcare providers must adhere to strict guidelines for prescribing controlled substances, including maintaining accurate records and conducting regular patient evaluations. Ongoing education in controlled substance prescribing is essential to mitigate risks associated with opioid use.
Conclusion
The settlement serves as a reminder of the legal and ethical responsibilities of healthcare providers in managing controlled substances.
